Resources
What Should My Business Test For? An Employer’s Guide to Drug Testing Panels
Panels are not a branding exercise—they are a contract between your policy, your lab’s menu, and (when applicable) federal or state rules. Here is how to choose without drowning in abbreviations.
· All articles · Industries · FAQ
If you have ever stared at an order form that asks for a “5-panel,” “10-panel,” “DOT panel,” or a string of three-letter codes, you are not alone. Drug testing panels are one of the most confusing parts of standing up or refreshing a workplace program—especially when someone in operations just wants a simple answer: “What are we testing for?”
The honest answer is that the right panel depends on your workforce (regulated or not), job risk, written policy, insurance or customer requirements, and the laboratory account your third-party administrator uses. The same nickname on two order forms can map to slightly different analytes at two labs. This guide gives employers a practical decision frame—not legal advice, and not a substitute for your TPA, MRO path, or counsel when programs cross state lines or regulated boundaries.
We write for HR, safety, DERs, and operations leaders who need clarity for budgets, supervisor training, and vendor conversations. Nothing here is guidance for test takers; it is program design context for people responsible for lawful, consistent testing.
Why “panel” labels are slippery
Employers often hear “five-panel” or “ten-panel” as if those phrases were standardized like shoe sizes. In practice, they are shorthand. A five-drug “SAMHSA-style” core is a common reference point in U.S. workplace testing, but your lab’s package name, cutoff levels, and optional add-ons still matter.
DOT-regulated drug tests use federally defined requirements for covered specimens—employers do not improvise substitutions. Non-DOT programs follow policy and state law, then align with whatever panels your lab and MRO can support. When someone says “we should test for everything,” translate that into: which risks, which roles, which legal constraints, and which reporting path.
Which panel fits which employer?
Start with program type, then narrow by risk and policy. The three buckets below are how most teams talk about it in the field—even though your order form may use different marketing names.
DOT / federally regulated testing
For DOT-covered drug tests, the analyte universe and collection rules are not something employers pick from a buffet. The U.S. Department of Transportation publishes requirements your consortium or TPA implements with an accredited laboratory. If you are managing safety-sensitive transportation employees, your job is to order the correct regulated test reason and modality—not to invent a custom “DOT++” panel on the side.
Pair this article with your operating administration’s expectations and your TPA’s written instructions. On-site collections still need the same discipline whether urine or oral fluid is authorized for your mode and effective dates.
Standard employer (often five-drug-style) panels
Many non-DOT employers begin with a focused panel that covers common drugs of abuse historically associated with workplace programs—frequently discussed as amphetamines, cocaine, marijuana (THC), opiates, and phencyclidine (PCP) in legacy five-panel language. Your lab may bundle these differently or rename the package.
This approach can suit broad pre-employment screening, routine random programs, or baseline policy testing when counsel agrees the panel matches handbook language and state constraints. Confirm whether your state limits or alters testing for marijuana (THC) for certain hire or discipline scenarios before you standardize.
Broader panels for higher-risk environments
Operations with acute safety risk, access to controlled substances, or post-incident scrutiny sometimes add prescription drug categories, expanded opioid coverage, barbiturates, benzodiazepines, propoxyphene, methadone, or other analytes the lab lists. “Ten-panel” is colloquial—count the analytes on the lab order, not the brochure headline.
Broader panels cost more, take more MRO attention when prescriptions are common, and should still reflect a policy your employees were told about. Bigger is not automatically better if supervisors cannot explain why a category is included.
Compare common panel approaches (plain English)
Use this table as a conversation starter with your TPA. Rows are concepts, not guarantees—your lab file is the source of truth for analytes, cutoffs, and reporting codes.
| Approach | What it usually means | Typical employer use |
|---|---|---|
| Regulated (DOT) drug test | Federally specified drug panel and procedures for covered testing—not interchangeable with a random non-DOT screen. | CDL and other DOT safety-sensitive roles; order through your DER/TPA with correct test reason. |
| Five-panel-style workplace bundle | Often centers on a small set of common drugs of abuse; exact drugs and codes vary by lab. | Baseline hiring or random programs when policy and state law align with a narrower screen. |
| Expanded / ten-panel-style (+) bundle | Adds categories such as benzodiazepines (BZO), barbiturates (BAR), methadone (MTD), or other analytes per lab package. | Higher-hazard sites, roles with prescription diversion risk, or policy-driven expansions. |
| Expanded opiate / opioid coverage | May add or emphasize semi-synthetic opioids (for example oxycodone) or fentanyl-class drugs depending on menu—terminology differs by lab. | Employers responding to opioid risk, certain post-accident programs, or customer contract language—verify analytes by name. |
| Alcohol programs | Workplace alcohol testing is often a separate workflow from a urine drug panel—breath testing under DOT rules, or policy-driven breath/EtG strategies for non-DOT when approved. | Post-accident windows, reasonable suspicion with behavioral cues, or random alcohol where policy and devices meet your plan. |
| Add-on: specimen validity testing (SVT) | Laboratory checks that help detect tampering or invalid specimens—scoped by lab and program. | Programs that need stronger integrity safeguards or face elevated substitution concerns—see section below. |
When someone asks whether you need a “5-panel vs 10-panel drug test for employers,” translate the question: which job categories, which incidents, which state rules, and which analytes appear on the laboratory requisition your TPA will actually file. The numbers are not universal law—they are shorthand.
Why employers add more than a “basic” panel
Expanded testing is usually driven by risk, contracts, or lessons learned—not by curiosity.
Alcohol: Many programs pair drug panels with breath alcohol testing where DOT requires it or where non-DOT policy and device standards support it. Ethyl glucuronide (EtG) or ethyl sulfate (EtS) urine testing is a different tool with different interpretation windows; use it only when policy and your medical review path make sense.
Fentanyl and potent synthetic opioids: Some employers add fentanyl-class testing when lab menus and counsel-approved policy language support it—especially in safety-sensitive environments or after near-miss events tied to opioids.
Prescription categories: Benzodiazepines (BZO), barbiturates (BAR), methadone (MTD), and other drugs matter when job duties, diversion risk, or healthcare-adjacent roles justify inclusion—and when MRO review can keep legitimate prescriptions from becoming HR chaos.
MDMA / ecstasy (MDMA): Appears on some expanded menus when employers want coverage beyond legacy “club drug” assumptions; confirm whether your lab groups it under amphetamine-class reporting or lists it separately.
Specimen validity testing (SVT): Employers serious about integrity may add validity testing appropriate to the specimen type so the lab can flag dilution, substitution, or other issues per its protocols—not as a substitute for observed collections when those are required.
Hair, oral fluid, or blood: Panel choice intersects with specimen type. Oral fluid and hair change detection windows and legal considerations; they do not magically replace thoughtful panel design. Match specimen, panel, and policy in one conversation with your TPA.
What is specimen validity testing (SVT)?
Specimen validity testing (SVT) is a set of laboratory checks on a submitted specimen to help determine whether it is consistent with a normal human sample and whether tampering indicators are present. The exact markers depend on the lab, the specimen (urine vs oral fluid, etc.), and the account configuration.
Employers use SVT as an integrity safeguard when substitution, dilution, or adulteration is a credible risk—high-turnover hiring, post-accident programs with reputational exposure, or sites with a history of problematic collections. SVT is not a personality test; it is a technical layer that works alongside clear chain-of-custody discipline and policy on refusals.
SVT results can trigger MRO or administrative review paths that differ from a straightforward negative or non-negative drug result. Align supervisor communications ahead of time so frontline leaders do not overstate what a flag means before review completes.
Adulterants and chemical masking
Adulterants are substances or household chemicals sometimes introduced to interfere with immunoassay or confirmatory steps. Laboratories configure validity checks to flag patterns consistent with oxidizing agents, pH extremes, or other anomalies that do not match a normal specimen profile. SVT does not replace observed collections where your program requires them, but it adds a documented lab signal when someone attempts chemical masking.
Dilution and abnormal fluid balance
Excessive fluid intake—or other manipulation—can produce dilute specimens that complicate interpretation. Validity testing may include creatinine, specific gravity, or related markers (per lab design) to identify samples that are not physiologically consistent with a typical void. Employers should define in policy how dilute results are treated after MRO or administrative review so supervisors do not improvise outcomes in the field.
Synthetic urine and substitution patterns
Synthetic products marketed to mimic human urine remain a real program risk in some environments. Validity markers and laboratory experience help identify specimens that do not behave like authentic human samples, but no single check is foolproof. Pair SVT with strong collection-site discipline, clear refusal rules, and observed collections when policy and regulation require them—especially for post-accident or reasonable-suspicion events with elevated stakes.
The Role of the Medical Review Officer (MRO)
Even with the right panel, a workplace drug test is only as trustworthy as the path that turns a laboratory finding into a verified, employer-facing result. For many DOT programs—and for numerous non-DOT programs configured with laboratory review—a Medical Review Officer (MRO) is the physician gate between raw data and the outcome your HR or safety team records.
The MRO reviews non-negative and other qualifying results under the rules that apply to your program. In DOT contexts, Part 40 defines how MRO verification works; in non-DOT programs, your policy, lab account, and counsel shape whether and how MRO review occurs. The MRO may contact the employee confidentially to explore legitimate medical explanations when allowed, then reports a verified result through your administrator’s channel.
From an employer standpoint, the MRO helps protect accuracy and consistency: fewer discipline decisions based on rumor, fewer arguments about whether a prescription was fairly considered, and a clearer record if a test is challenged later. We perform collections and chain-of-custody execution; we do not act as the MRO or provide legal advice—your TPA and counsel define how results flow into employment actions.
Substance and panel glossary (employer cheat sheet)
Marijuana (THC)
Cannabis testing targets THC-related metabolites or parent compounds depending on specimen and methodology. State marijuana laws vary widely; some employers exclude THC from certain actions or panels. Your policy, counsel, and lab menu must agree before you promise a particular outcome to leadership.
Cocaine (COC)
Cocaine and its primary metabolites are common inclusions on workplace panels when policy covers stimulant risk. Reporting is laboratory- and cutoff-specific.
Opiates vs. expanded opioids
Legacy “opiate” panels often targeted morphine/codeine/heroin-class chemistry language; many employers now add expanded opioid coverage for semi-synthetic drugs (for example oxycodone, hydrocodone) where the lab menu supports it. Names on invoices do not always match clinical speech—read the analyte list.
Fentanyl
Fentanyl and some analogs may be available as add-ons or embedded in advanced opioid bundles. Inclusion should follow risk assessment and policy updates, not hallway decisions after one news story.
Amphetamines (AMP / MAMP)
Amphetamine screening may pick up prescription stimulants and, depending on lab design, may relate to MDMA chemistry discussions. MRO review is often central to separating legitimate prescription use from policy violations when prescriptions exist.
Phencyclidine (PCP)
PCP remains a classic panel inclusion on many standard bundles even though prevalence varies by workforce. It is a reminder that “standard” panels inherit history, not just current incident data.
MDMA / ecstasy
MDMA may appear on expanded panels under its own code or as part of broader stimulant coverage. If your supervisors reference “party drugs,” translate that into the specific analytes on the order.
Barbiturates (BAR)
Older sedative-hypnotic class; still relevant for certain medical contexts and diversion concerns. Usually an expanded-panel item, not a default for every employer.
Benzodiazepines (BZO)
Anti-anxiety and sedative medications appear in many expanded workplace panels. Expect more MRO outreach to employees when legitimate prescriptions are common in your population.
Methadone (MTD)
Often listed on expanded panels when employers want coverage distinct from generic opiate bundles. Interpretation and MRO paths should be understood before rollout.
Methaqualone (MTQ)
Less common today but may still appear on broad menus. Include only when policy and medical review expectations justify the complexity.
Propoxyphene (PPX)
Legacy analgesic; occasionally still referenced on broad panels. Confirm whether your lab still offers meaningful medical review pathways for low-prevalence analytes.
Alcohol: breath vs. EtG / EtS
Workplace alcohol programs often use evidential breath testing (EBT) devices for DOT or policy-driven tests with defined observation rules. Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are urinary markers sometimes used in non-DOT contexts when policy and timelines are appropriate—they measure recent exposure windows differently than a breath snapshot. Phosphatidylethanol (PEth) is a blood-based alcohol marker used in specialized monitoring—not a drop-in substitute for DOT breath rules.
How to choose the right program
Walk through these lenses in order; the first one that forces a special rule usually wins.
By industry and customer contracts
Transportation, energy, manufacturing, and healthcare-adjacent employers often face contract clauses, insurer questionnaires, or owner-client rules that name minimum testing expectations. Start from those documents, then map them to lab capability.
By job risk
Higher kinetic energy, lone work, machinery, or medication access pushes programs toward broader panels, alcohol coverage, and clearer post-accident triggers. Desk populations may still need rigorous testing when policy requires it, but the analyte list should match actual risk and counsel guidance.
By DOT vs. non-DOT
By policy goals
Pre-employment deterrence, random deterrence, post-incident documentation, and reasonable suspicion each carry different time pressures. Post-accident and suspicion events need orders that match both panel and specimen to the scenario (for example, alcohol plus drugs when policy requires).
By testing reason: pre-employment, random, post-accident
Pre-employment panels should match offer letters and state notice rules. Random programs need stable, published panel definitions so selections feel fair. Post-accident testing should follow written triggers so supervisors are not inventing scope on the worst day of the quarter.
Before you lock the panel in writing
Ask your TPA for a one-page analyte list with common abbreviations, cutoff notes, and MRO handling expectations. Load that into supervisor FAQs so the break room rumor mill does not become your training plan.
Revisit panels after major legal changes in marijuana (THC) rules, insurance renewals, or serious incidents. A panel that made sense three years ago can drift out of alignment with policy or lab menus faster than HR remembers.
Match the right panel to your program
Tell us DOT vs non-DOT, roles, and testing reasons—we help align on-site and mobile collections with the orders your TPA and lab expect.